Marc Goodman Analyst PerformanceSenior Managing Director, Neuroscience at Leerink PartnersMarc Goodman is a stock analyst at Leerink Partners focused in the medical sector, covering 26 publicly traded companies. Over the past year, Marc Goodman has issued 15 stock ratings, including buy and hold recommendations. While full access to Marc Goodman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Marc Goodman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings49 Last 10 YearsBuy Recommendations75.51% 37 Buy RatingsCompanies Covered26 Unique Companies Ratings Distribution49RatingsDistribution of strong buy, buy, hold, and sell ratings by Marc Goodman.RatingPercentageCount Strong Buy0.0%0 ratings Buy75.5%37 ratings Hold24.5%12 ratings Sell0.0%0 ratingsOut of 49 total stock ratings issued by Marc Goodman at Leerink Partners, the majority (75.5%) have been Buy recommendations, followed by 24.5% Hold.Best & Worst CallsBest Call0000.0%EOLSApr 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%BHCDec 2015Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ65.4% of companies on NASDAQ17 companiesNYSE34.6% of companies on NYSE9 companiesMarc Goodman, an analyst at Leerink Partners, currently covers 26 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical22 companies84.6%Manufacturing4 companies15.4%Marc Goodman of Leerink Partners specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE10 companies38.5%LARGE CAP PHARMA4 companies15.4%MED - DRUGS3 companies11.5%PHARMACEUTICAL PREPARATIONS2 companies7.7%Miscellaneous2 companies7.7%MED - GENERIC DRG2 companies7.7%BIOTECHNOLOGY1 company3.8%SURGICAL, MEDICAL, AND DENTAL INSTRUMENTS AND SUPPLIES1 company3.8%MED PRODUCTS1 company3.8% About Marc GoodmanMarc Goodman is a Senior Research Analyst at Leerink Partners covering Neuroscience and Ophthalmology. Prior to joining the Firm in 2018, Marc was most recently a Managing Director and U.S. Healthcare Analyst at UBS Investment Bank, where he focused on large-cap and specialty pharmaceuticals sectors. Prior to UBS, he covered specialty pharmaceuticals and generics sectors for over 15 years as a Managing Director at Crédit Suisse AG and as an Executive Director at Morgan Stanley. Marc has been ranked by Institutional Investor as a top analyst in Specialty Pharmaceuticals for well over a decade and has also expanded his coverage and interests into global and emerging biopharmaceutical companies in recent years. He earned his MBA from The Ohio State University and his B.A. in Economics from Tufts University. Marc Goodman's Ratings History at Leerink Partners Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsDNLIDenali Therapeutics4/22/2026Lower Price Target$20.42$35.00Outperform$0.0000.00% ROIDFTXDefinium Therapeutics4/22/2026Boost Price Target$22.83$30.00Outperform$0.0000.00% ROINBIXNeurocrine Biosciences4/22/2026Boost Price Target$130.76$170.00Outperform$0.0000.00% ROIMANEMANE4/22/2026Boost Price Target$76.09$90.00Outperform$0.0000.00% ROIJAZZJazz Pharmaceuticals4/22/2026Boost Price Target$201.27$225.00Outperform$0.0000.00% ROIBHVNBiohaven3/3/2026Reiterated Rating$10.66$15.00Outperform$0.0000.00% ROISGPSpyglass Pharma3/3/2026Initiated Coverage$26.73$42.00Outperform$0.0000.00% ROIMANEMANE3/2/2026Initiated Coverage$45.70$75.00Outperform$0.0000.00% ROIAXSMAxsome Therapeutics1/28/2026Boost Price Target$184.56$205.00Outperform$0.0000.00% ROINMRANeumora Therapeutics1/12/2026Initiated Coverage$2.22$8.00Outperform$0.0000.00% ROIMPLTMaplight Therapeutics11/21/2025Initiated Coverage$13.29$30.00Outperform$0.0000.00% ROIOVIDOvid Therapeutics11/17/2025Initiated Coverage$1.31$5.00Outperform$0.0000.00% ROIAVDLAvadel Pharmaceuticals10/23/2025Reiterated Rating$18.56$18.50Market Perform$0.0000.00% ROILBRXLB Pharmaceuticals10/6/2025Initiated Coverage$15.05$34.00Outperform$0.0000.00% ROIBHVNBiohaven8/12/2025Lower Price Target$13.46$50.00Outperform$0.0000.00% ROIAMLXAmylyx Pharmaceuticals5/7/2025Upgrade$4.65$10.00Outperform$00.0000.00% ROIOPTOpthea3/25/2025Downgrade$3.41$1.00Market Perform$0.0000.00% ROIAXSMAxsome Therapeutics2/10/2025Boost Price Target$127.08$150.00Outperform$000.0000.00% ROIAMLXAmylyx Pharmaceuticals10/18/2024Set Price Target$4.67$4.00Market Perform$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenJefferies Financial GroupUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.The Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
